Last updated: March 12, 2026
What are the key facts of the case?
Depomed, Inc., a specialty pharmaceutical company, filed patent infringement litigation against Sun Pharma Global FZE in the U.S. District Court for the Northern District of California. The case number is 3:11-cv-03553. The dispute involves allegations that Sun Pharma infringed on patents owned by Depomed related to controlled-release formulations of certain drugs. The patents at issue include U.S. Patent No. 7,649,061 and U.S. Patent No. 7,645,608, which cover extended-release formulations aimed at treating pain and other conditions.
The litigation began in 2011 when Depomed filed suit after Sun Pharma launched a generic product believed to infringe those patents. Sun Pharma contended the patents were invalid and/or not infringed.
When did the case progress through key stages?
- Complaint filing: July 1, 2011.
- Initial rulings: The court examined the validity and infringement issues during early motions.
- Markman hearing: Conducted in 2012 to interpret patent claim language.
- Summary judgment motions: Filed by both parties in 2013, arguing for or against patent validity and infringement.
- Trial: The case was scheduled for trial in late 2013 but was delayed multiple times—primarily due to procedural and settlement negotiations.
- Settlement: The case was settled in 2014 before a final court decision.
What were the primary legal issues?
Patent validity
Sun Pharma challenged the patents’ validity based on allegations of obviousness and lack of inventive step, referencing prior art documents that predate the patents’ filing date.
Patent infringement
Depomed claimed that Sun Pharma’s generic formulation products infringed on the patents’ claims concerning release mechanisms and drug formulations.
Declaratory judgment
Sun Pharma filed for a declaratory judgment of non-infringement and invalidity, prompting the litigation.
What was the outcome?
The case was settled in 2014, with Sun Pharma agreeing to license the patents from Depomed and pay an undisclosed fee. No final court judgment on patent validity or infringement was issued, as the settlement rendered those issues moot.
What are the implications for pharmaceutical patent litigation?
- Settlement trends: Pharmaceutical patent disputes often end with licensing agreements rather than final judgments.
- Patent lifecycles: Patent challenges on obviousness and inventive step are common strategies to delay generic entry.
- Market access: Licensing agreements can enable generic entry while respecting patent rights.
What does this case reveal about patent infringement litigation?
This case demonstrates the importance of patent claims related to formulation specifics, especially for controlled-release drugs. It highlights the strategic use of validity challenges and settlement negotiations to manage litigation risks and market access.
How does this case compare to similar litigations?
Compared to high-profile disputes (e.g., Abbreviated New Drug Application cases), the Depomed v. Sun Pharma case settled early, reflecting a negotiation-centric resolution typical in the industry.
Key Takeaways
- Patent litigation in the pharmaceutical industry often concludes with licensing agreements.
- Challenges to patent validity focus on obviousness based on prior art.
- Settlement can occur before a court ruling consolidates patent rights.
- Patent claims on drug formulations are central in infringement disputes.
- Early settlement reduces uncertainty and preserves market access timelines.
FAQs
1. What patents were involved in the case?
U.S. Patent Nos. 7,649,061 and 7,645,608.
2. Why did Sun Pharma challenge the patents?
Due to allegations that the patents were obvious or invalid based on prior art.
3. How did the case conclude?
With a settlement agreement in 2014, including licensing arrangements.
4. What legal issues are common in such cases?
Patent validity (obviousness), infringement, and invalidity defenses.
5. Can patent disputes influence drug pricing?
Yes, settlement and licensing affect drug exclusivity periods and generic entry, impacting pricing.
References
- Court case filings for Depomed, Inc. v. Sun Pharma Global FZE, 3:11-cv-03553, Northern District of California.
- U.S. Patent No. 7,649,061 (filed 2007, issued 2010).
- U.S. Patent No. 7,645,608 (filed 2007, issued 2010).
- Court docket and settlement reports, 2014 (PACER).
